Document Detail


Metastatic prostate cancer: assessment of response to systemic therapy.
MedLine Citation:
PMID:  9050137     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The use of standard assessment criteria to evaluate therapeutic responses in patients with advanced prostate cancer is confounded by the high percentage of patients with bone-only metastatic disease. In an effort to develop a reliable means of assessing the activity of various therapeutic interventions, the role of prostate-specific antigen (PSA) as a response parameter is being actively evaluated. The precise role of PSA in this setting remains undefined as there is limited and sometimes conflicting findings in the literature. Additionally, there is emerging data to suggest that various therapeutic agents may influence PSA expression in a manner unrelated to the impact on tumor growth. Given the high percentage of patients with bone metastases, investigators have been actively evaluating a series of new markers of bone turnover; however, the lack of acceptable specificity limits the clinical usefulness of this approach. The role of palliative endpoints such as pain and quality of life measures have been shown to be both feasible and clinically relevant in the assessment of response in patients with symptoms of advanced disease. The emergence of an enlarging subset of asymptomatic patients with PSA-only evidence of metastatic disease presents a new and pressing challenge to clinicians to develop reliable new methods of assessing disease response to therapeutic interventions.
Authors:
R Dreicer
Related Documents :
14572747 - Immediate treatment with bicalutamide 150mg as adjuvant therapy significantly reduces t...
19035857 - Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screenin...
17269617 - Pathological aspects of prostate cancer aggressive behavior. personal experience in dif...
9610567 - The usefulness of prostate-specific antigen (psa) density in patients with intermediate...
25407827 - Psma-targeting iron oxide magnetic nanoparticles enhance mri of preclinical prostate ca...
15586237 - Silymarin and skin cancer prevention: anti-inflammatory, antioxidant and immunomodulato...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Seminars in urologic oncology     Volume:  15     ISSN:  1081-0943     ISO Abbreviation:  Semin. Urol. Oncol.     Publication Date:  1997 Feb 
Date Detail:
Created Date:  1997-04-29     Completed Date:  1997-04-29     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  9514993     Medline TA:  Semin Urol Oncol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  28-32     Citation Subset:  IM    
Affiliation:
Department of Internal Medicine, University of Iowa College of Medicine, Iowa City, USA. Robert-Dreicer@uiowa.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents / pharmacology
Bone Neoplasms / blood*,  secondary*
Humans
Male
Neoplasm Metastasis
Neoplasms, Hormone-Dependent / blood*,  therapy
Palliative Care
Prostate-Specific Antigen / biosynthesis,  blood*
Prostatic Neoplasms / blood*,  pathology,  therapy
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; EC 3.4.21.77/Prostate-Specific Antigen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Other chemotherapy regimens including mitoxantrone and suramin.
Next Document:  Novel therapies for advanced prostate cancer.